Investment
Features
FeesSafety
Academy
More
Pluang+

CLARITY Act could boost Circle and Hyperliquid as stablecoin regulations near approval

Market News
01 Aug 2026
Crypto Briefing
View Source
Bullish
pluang ai news

Bob Diamond, former Barclays CEO, predicts the CLARITY Act will pass by the end of 2026, benefiting Circle and Hyperliquid. The act sets clear rules for stablecoin yields, reducing legal uncertainty and enabling product expansion. Circle's USDC stablecoin is already dominant in compliant markets, while Hyperliquid's partnership with Coinbase and Circle's token stake aim to attract institutional traders. However, the bill's passage is not guaranteed, and Hyperliquid faces competition in a fast-moving trading space.

More News

New AI tech cuts energy use up to 50% and boosts server capacity on existing NVIDIA hardware.

New AI tech cuts energy use up to 50% and boosts server capacity on existing NVIDIA hardware.

Trust Carbon Infrastructure unveiled its HXS compute-efficiency layer, which reduces energy consumption by up to 50.5% and increases server throughput by 167% on NVIDIA H100 GPUs without changing AI model outputs. Tested on models from Alibaba, Meta,...

Market News
Bullish
4 hours ago
Dice rolls can secure Bitcoin wallets offline, but most users find the process too slow and error-prone.

Dice rolls can secure Bitcoin wallets offline, but most users find the process too slow and error-prone.

Bitcoin wallets can be secured using randomness generated by rolling a six-sided die about 50 to 99 times, providing strong entropy without relying on electronic devices. This method gained attention after a Coldcard hardware wallet flaw exposed keys...

Protocol Fundamentals
Neutral
4 hours ago
Applied Materials posts record Q2 revenue $7.91B, raises 2026 growth outlook above 30%.

Applied Materials posts record Q2 revenue $7.91B, raises 2026 growth outlook above 30%.

Applied Materials reported a record Q2 FY2026 revenue of $7.91 billion, an 11% increase year-over-year, and a non-GAAP EPS of $2.86, up 20%. The company raised its equipment growth guidance for calendar year 2026 to over 30%, driven by strong perform...

Company Fundamentals
Bullish
4 hours ago
FDA clears Medicus Pharma's Phase 2b trial for SkinJect to treat Gorlin syndrome patients

FDA clears Medicus Pharma's Phase 2b trial for SkinJect to treat Gorlin syndrome patients

Medicus Pharma received FDA clearance to start a Phase 2b clinical trial for SkinJect, a minimally invasive treatment targeting basal cell carcinoma in Gorlin syndrome patients. This rare genetic disorder causes multiple basal cell lesions, with no c...

Market News
Bullish
4 hours ago
Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.

Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.

Collegium Pharmaceutical is transforming from a pain-management company to a central nervous system (CNS) platform by acquiring AZSTARYS, an ADHD drug franchise. The $650 million acquisition, funded by cash and debt, is projected to generate $60–70 m...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App